About
Vinci Pharmaceuticals develops a proprietary needle-free drug delivery platform, EPIPLANT™, to treat retinal diseases such as Diabetic Macular Edema (DME) and Intermediate Age-related Macular Degeneration (iAMD).
Explore Vinci Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.